The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study
The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-st...
Gespeichert in:
| Veröffentlicht in: | Archivum Immunologiae et Therapiae Experimentalis 2023-12, Vol.71 (1), p.8-8, Article 8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 1 |
| container_start_page | 8 |
| container_title | Archivum Immunologiae et Therapiae Experimentalis |
| container_volume | 71 |
| creator | Sadeghdoust, Mohammadamin Aligolighasemabadi, Farnaz Dehesh, Tania Taefehshokr, Nima Sadeghdoust, Adel Kotfis, Katarzyna Hashemiattar, Amirhossein Ravandi, Amir Aligolighasemabadi, Neda Vakili, Omid Grabarek, Beniamin Staszkiewicz, Rafał Łos, Marek J. Mokarram, Pooneh Ghavami, Saeid |
| description | The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching
.
Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Graphical Abstract |
| doi_str_mv | 10.1007/s00005-023-00672-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9972324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780764520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-38f95fcad312fe7dbecce90576611205d626ae6c8db8801f5478ad58cb57731c3</originalsourceid><addsrcrecordid>eNp9UU1v1DAQtRCILoU_wAFZ4sIl4I_ETjggVdsWKm3VihbEzXIcZ9dVYm9tB7S_o3-4U1LKxwFfPPa8eTNvHkIvKXlLCZHvEoFTFYTxghAhWUEfoQUVghZlQ-VjtIB0WRDRfNtDz1K6ghevaPkU7XFRV5yJZoFuLjcWH_W9NTnh0OOLrLPzEHr82aatizqHuMMXu3Gbw5iw9h0-n4YxeA3fx66NIbmEncfLs68nhwVt8DkwWA90P1ze4EOnW5ttwqd2GFye0nt8gFfBryHunNcDPp2G7AxU2Ajtp273HD3p9ZDsi_t7H305PrpcfipWZx9PlgerwpSyzAWv-6bqje44Zb2VXWuNsQ2pJGyAMlJ1ggltham7tq4J7atS1rqratNWUnJq-D76MPNup3a03d0IUQ9qG90I4lTQTv2d8W6j1uG7ahrJOCuB4M09QQzXk01ZjS4Z0Km9DVNSTNZEirJiBKCv_4FehSmC_BlVc0GlABSbUQbWmqLtH4ahRN15rmbPFXiufnquKBS9-lPGQ8kvkwHAZ0CClF_b-Lv3f2hvAYhruYc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780836176</pqid></control><display><type>article</type><title>The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study</title><source>MEDLINE</source><source>De Gruyter Journals - Open Access</source><creator>Sadeghdoust, Mohammadamin ; Aligolighasemabadi, Farnaz ; Dehesh, Tania ; Taefehshokr, Nima ; Sadeghdoust, Adel ; Kotfis, Katarzyna ; Hashemiattar, Amirhossein ; Ravandi, Amir ; Aligolighasemabadi, Neda ; Vakili, Omid ; Grabarek, Beniamin ; Staszkiewicz, Rafał ; Łos, Marek J. ; Mokarram, Pooneh ; Ghavami, Saeid</creator><creatorcontrib>Sadeghdoust, Mohammadamin ; Aligolighasemabadi, Farnaz ; Dehesh, Tania ; Taefehshokr, Nima ; Sadeghdoust, Adel ; Kotfis, Katarzyna ; Hashemiattar, Amirhossein ; Ravandi, Amir ; Aligolighasemabadi, Neda ; Vakili, Omid ; Grabarek, Beniamin ; Staszkiewicz, Rafał ; Łos, Marek J. ; Mokarram, Pooneh ; Ghavami, Saeid</creatorcontrib><description>The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching
.
Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Graphical Abstract</description><identifier>ISSN: 0004-069X</identifier><identifier>EISSN: 1661-4917</identifier><identifier>DOI: 10.1007/s00005-023-00672-1</identifier><identifier>PMID: 36853269</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Computed tomography ; Coronaviruses ; Cough ; COVID-19 ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - epidemiology ; Dyspnea ; Fibrosis ; Humans ; Immunology ; Lung diseases ; Original ; Original Article ; Pharmacology/Toxicology ; Prospective Studies ; Pulmonary fibrosis ; Pulmonary Fibrosis - drug therapy ; Respiration ; Statins</subject><ispartof>Archivum Immunologiae et Therapiae Experimentalis, 2023-12, Vol.71 (1), p.8-8, Article 8</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-38f95fcad312fe7dbecce90576611205d626ae6c8db8801f5478ad58cb57731c3</citedby><cites>FETCH-LOGICAL-c474t-38f95fcad312fe7dbecce90576611205d626ae6c8db8801f5478ad58cb57731c3</cites><orcidid>0000-0001-8430-1369 ; 0000-0002-9615-2169 ; 0000-0001-6457-7886 ; 0000-0003-0083-0672 ; 0000-0001-9518-1411 ; 0000-0003-4579-5911 ; 0000-0003-1633-7145 ; 0000-0001-6039-2921 ; 0000-0002-9717-0473 ; 0000-0002-9103-872X ; 0000-0002-8389-6097 ; 0000-0001-5948-508X ; 0000-0001-5055-1618</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36853269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sadeghdoust, Mohammadamin</creatorcontrib><creatorcontrib>Aligolighasemabadi, Farnaz</creatorcontrib><creatorcontrib>Dehesh, Tania</creatorcontrib><creatorcontrib>Taefehshokr, Nima</creatorcontrib><creatorcontrib>Sadeghdoust, Adel</creatorcontrib><creatorcontrib>Kotfis, Katarzyna</creatorcontrib><creatorcontrib>Hashemiattar, Amirhossein</creatorcontrib><creatorcontrib>Ravandi, Amir</creatorcontrib><creatorcontrib>Aligolighasemabadi, Neda</creatorcontrib><creatorcontrib>Vakili, Omid</creatorcontrib><creatorcontrib>Grabarek, Beniamin</creatorcontrib><creatorcontrib>Staszkiewicz, Rafał</creatorcontrib><creatorcontrib>Łos, Marek J.</creatorcontrib><creatorcontrib>Mokarram, Pooneh</creatorcontrib><creatorcontrib>Ghavami, Saeid</creatorcontrib><title>The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study</title><title>Archivum Immunologiae et Therapiae Experimentalis</title><addtitle>Arch. Immunol. Ther. Exp</addtitle><addtitle>Arch Immunol Ther Exp (Warsz)</addtitle><description>The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching
.
Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Graphical Abstract</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Computed tomography</subject><subject>Coronaviruses</subject><subject>Cough</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Dyspnea</subject><subject>Fibrosis</subject><subject>Humans</subject><subject>Immunology</subject><subject>Lung diseases</subject><subject>Original</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><subject>Prospective Studies</subject><subject>Pulmonary fibrosis</subject><subject>Pulmonary Fibrosis - drug therapy</subject><subject>Respiration</subject><subject>Statins</subject><issn>0004-069X</issn><issn>1661-4917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQtRCILoU_wAFZ4sIl4I_ETjggVdsWKm3VihbEzXIcZ9dVYm9tB7S_o3-4U1LKxwFfPPa8eTNvHkIvKXlLCZHvEoFTFYTxghAhWUEfoQUVghZlQ-VjtIB0WRDRfNtDz1K6ghevaPkU7XFRV5yJZoFuLjcWH_W9NTnh0OOLrLPzEHr82aatizqHuMMXu3Gbw5iw9h0-n4YxeA3fx66NIbmEncfLs68nhwVt8DkwWA90P1ze4EOnW5ttwqd2GFye0nt8gFfBryHunNcDPp2G7AxU2Ajtp273HD3p9ZDsi_t7H305PrpcfipWZx9PlgerwpSyzAWv-6bqje44Zb2VXWuNsQ2pJGyAMlJ1ggltham7tq4J7atS1rqratNWUnJq-D76MPNup3a03d0IUQ9qG90I4lTQTv2d8W6j1uG7ahrJOCuB4M09QQzXk01ZjS4Z0Km9DVNSTNZEirJiBKCv_4FehSmC_BlVc0GlABSbUQbWmqLtH4ahRN15rmbPFXiufnquKBS9-lPGQ8kvkwHAZ0CClF_b-Lv3f2hvAYhruYc</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Sadeghdoust, Mohammadamin</creator><creator>Aligolighasemabadi, Farnaz</creator><creator>Dehesh, Tania</creator><creator>Taefehshokr, Nima</creator><creator>Sadeghdoust, Adel</creator><creator>Kotfis, Katarzyna</creator><creator>Hashemiattar, Amirhossein</creator><creator>Ravandi, Amir</creator><creator>Aligolighasemabadi, Neda</creator><creator>Vakili, Omid</creator><creator>Grabarek, Beniamin</creator><creator>Staszkiewicz, Rafał</creator><creator>Łos, Marek J.</creator><creator>Mokarram, Pooneh</creator><creator>Ghavami, Saeid</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8430-1369</orcidid><orcidid>https://orcid.org/0000-0002-9615-2169</orcidid><orcidid>https://orcid.org/0000-0001-6457-7886</orcidid><orcidid>https://orcid.org/0000-0003-0083-0672</orcidid><orcidid>https://orcid.org/0000-0001-9518-1411</orcidid><orcidid>https://orcid.org/0000-0003-4579-5911</orcidid><orcidid>https://orcid.org/0000-0003-1633-7145</orcidid><orcidid>https://orcid.org/0000-0001-6039-2921</orcidid><orcidid>https://orcid.org/0000-0002-9717-0473</orcidid><orcidid>https://orcid.org/0000-0002-9103-872X</orcidid><orcidid>https://orcid.org/0000-0002-8389-6097</orcidid><orcidid>https://orcid.org/0000-0001-5948-508X</orcidid><orcidid>https://orcid.org/0000-0001-5055-1618</orcidid></search><sort><creationdate>20231201</creationdate><title>The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study</title><author>Sadeghdoust, Mohammadamin ; Aligolighasemabadi, Farnaz ; Dehesh, Tania ; Taefehshokr, Nima ; Sadeghdoust, Adel ; Kotfis, Katarzyna ; Hashemiattar, Amirhossein ; Ravandi, Amir ; Aligolighasemabadi, Neda ; Vakili, Omid ; Grabarek, Beniamin ; Staszkiewicz, Rafał ; Łos, Marek J. ; Mokarram, Pooneh ; Ghavami, Saeid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-38f95fcad312fe7dbecce90576611205d626ae6c8db8801f5478ad58cb57731c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Computed tomography</topic><topic>Coronaviruses</topic><topic>Cough</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Dyspnea</topic><topic>Fibrosis</topic><topic>Humans</topic><topic>Immunology</topic><topic>Lung diseases</topic><topic>Original</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><topic>Prospective Studies</topic><topic>Pulmonary fibrosis</topic><topic>Pulmonary Fibrosis - drug therapy</topic><topic>Respiration</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadeghdoust, Mohammadamin</creatorcontrib><creatorcontrib>Aligolighasemabadi, Farnaz</creatorcontrib><creatorcontrib>Dehesh, Tania</creatorcontrib><creatorcontrib>Taefehshokr, Nima</creatorcontrib><creatorcontrib>Sadeghdoust, Adel</creatorcontrib><creatorcontrib>Kotfis, Katarzyna</creatorcontrib><creatorcontrib>Hashemiattar, Amirhossein</creatorcontrib><creatorcontrib>Ravandi, Amir</creatorcontrib><creatorcontrib>Aligolighasemabadi, Neda</creatorcontrib><creatorcontrib>Vakili, Omid</creatorcontrib><creatorcontrib>Grabarek, Beniamin</creatorcontrib><creatorcontrib>Staszkiewicz, Rafał</creatorcontrib><creatorcontrib>Łos, Marek J.</creatorcontrib><creatorcontrib>Mokarram, Pooneh</creatorcontrib><creatorcontrib>Ghavami, Saeid</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archivum Immunologiae et Therapiae Experimentalis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadeghdoust, Mohammadamin</au><au>Aligolighasemabadi, Farnaz</au><au>Dehesh, Tania</au><au>Taefehshokr, Nima</au><au>Sadeghdoust, Adel</au><au>Kotfis, Katarzyna</au><au>Hashemiattar, Amirhossein</au><au>Ravandi, Amir</au><au>Aligolighasemabadi, Neda</au><au>Vakili, Omid</au><au>Grabarek, Beniamin</au><au>Staszkiewicz, Rafał</au><au>Łos, Marek J.</au><au>Mokarram, Pooneh</au><au>Ghavami, Saeid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study</atitle><jtitle>Archivum Immunologiae et Therapiae Experimentalis</jtitle><stitle>Arch. Immunol. Ther. Exp</stitle><addtitle>Arch Immunol Ther Exp (Warsz)</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>71</volume><issue>1</issue><spage>8</spage><epage>8</epage><pages>8-8</pages><artnum>8</artnum><issn>0004-069X</issn><eissn>1661-4917</eissn><abstract>The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching
.
Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Graphical Abstract</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>36853269</pmid><doi>10.1007/s00005-023-00672-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8430-1369</orcidid><orcidid>https://orcid.org/0000-0002-9615-2169</orcidid><orcidid>https://orcid.org/0000-0001-6457-7886</orcidid><orcidid>https://orcid.org/0000-0003-0083-0672</orcidid><orcidid>https://orcid.org/0000-0001-9518-1411</orcidid><orcidid>https://orcid.org/0000-0003-4579-5911</orcidid><orcidid>https://orcid.org/0000-0003-1633-7145</orcidid><orcidid>https://orcid.org/0000-0001-6039-2921</orcidid><orcidid>https://orcid.org/0000-0002-9717-0473</orcidid><orcidid>https://orcid.org/0000-0002-9103-872X</orcidid><orcidid>https://orcid.org/0000-0002-8389-6097</orcidid><orcidid>https://orcid.org/0000-0001-5948-508X</orcidid><orcidid>https://orcid.org/0000-0001-5055-1618</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-069X |
| ispartof | Archivum Immunologiae et Therapiae Experimentalis, 2023-12, Vol.71 (1), p.8-8, Article 8 |
| issn | 0004-069X 1661-4917 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9972324 |
| source | MEDLINE; De Gruyter Journals - Open Access |
| subjects | Biomedical and Life Sciences Biomedicine Computed tomography Coronaviruses Cough COVID-19 Diabetes Diabetes mellitus Diabetes Mellitus - drug therapy Diabetes Mellitus - epidemiology Dyspnea Fibrosis Humans Immunology Lung diseases Original Original Article Pharmacology/Toxicology Prospective Studies Pulmonary fibrosis Pulmonary Fibrosis - drug therapy Respiration Statins |
| title | The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A48%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effects%20of%20Statins%20on%20Respiratory%20Symptoms%20and%20Pulmonary%20Fibrosis%20in%20COVID-19%20Patients%20with%20Diabetes%20Mellitus:%20A%20Longitudinal%20Multicenter%20Study&rft.jtitle=Archivum%20Immunologiae%20et%20Therapiae%20Experimentalis&rft.au=Sadeghdoust,%20Mohammadamin&rft.date=2023-12-01&rft.volume=71&rft.issue=1&rft.spage=8&rft.epage=8&rft.pages=8-8&rft.artnum=8&rft.issn=0004-069X&rft.eissn=1661-4917&rft_id=info:doi/10.1007/s00005-023-00672-1&rft_dat=%3Cproquest_pubme%3E2780764520%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780836176&rft_id=info:pmid/36853269&rfr_iscdi=true |